The U.S. FDA granted marketing authorization for ProSense in October 2025 for use in low-risk early-stage breast cancer, specifically for women aged 70 and over or those unsuitable for surgery. Market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results